- United States
- /
- Biotech
- /
- NasdaqCM:SLNO
What Should You Know About Soleno Therapeutics Inc's (NASDAQ:SLNO) Earnings Trajectory?
Market analysts' prospects for next year seems relatively unexciting, with earnings continuing to flop around in the negative territory, arriving at -US$12.25M in 2019. Additionally, earnings should fall further in the following year, declining to -US$17.00M in 2020 and -US$19.12M in 2021.
Even though it is helpful to understand the rate of growth each year relative to today’s value, it may be more insightful determining the rate at which the business is moving on average every year. The pro of this technique is that we can get a better picture of the direction of Soleno Therapeutics's earnings trajectory over the long run, irrespective of near term fluctuations, be more volatile. To calculate this rate, I've appended a line of best fit through the forecasted earnings by market analysts. The slope of this line is the rate of earnings growth, which in this case is 30.63%. This means, we can expect Soleno Therapeutics will grow its earnings by 30.63% every year for the next few years.
Next Steps:
For Soleno Therapeutics, there are three fundamental factors you should further examine:
- Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
- Future Earnings: How does SLNO's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High-Growth Alternatives: Are there other high-growth stocks you could be holding instead of SLNO? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Simply Wall St analyst Simply Wall St and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
About NasdaqCM:SLNO
Soleno Therapeutics
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
High growth potential and good value.
Market Insights
Community Narratives
